Rheumatoid arthritis
Drug research and approvals for rheumatoid arthritis: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 16, 2026, 297 studies of rheumatoid arthritis are recruiting on ClinicalTrials.gov, Health Canada has authorized 58 drug trials for it since 2013, FDA has 5 approved and 12 open orphan designations naming it, and the EU has 41 authorised medicines for it.
- Recruiting worldwide: 297
- Trials authorized in Canada: 58
- FDA orphan approvals: 5
- EU medicines: 41
Recruiting Now
Newest start dates first, of 297 recruiting on ClinicalTrials.gov ↗- Application of the Personalized N-of-1 Trial Design in Patients With Rheumatoid ArthritisNCT06016517 · Not reported · Tufts Medical Center · starts Dec 1, 2026
- Pain Phenotyping of Rheumatic Diseases - An Observational StudyNCT07829497 · Not reported · National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) · starts Nov 9, 2026
- A Study of BMS-986528 in Participants With Refractory Rheumatoid ArthritisNCT07412704 · Phase 1 / Phase 2 · Bristol-Myers Squibb · starts Oct 6, 2026
- FT839 in Autoimmune DiseasesNCT07800871 · Phase 1 / Phase 2 · Fate Therapeutics · starts Oct 1, 2026
- A Study of ATG-201 in Adult Participants With Autoimmune DiseasesNCT07732309 · Phase 1 · Antengene Biologics Limited · starts Sep 26, 2026
- Study of PTC844 in Participants With Active Rheumatoid ArthritisNCT07779616 · Phase 2 · PTC Therapeutics · starts Sep 24, 2026
- A Trial in Healthy Adult Participants and Adults With Autoimmune Diseases to Test How HBM7020 is Tolerated and How it…NCT07649265 · Phase 1 · Otsuka Pharmaceutical Development & Commercialization, Inc. · starts Sep 24, 2026
- The Effect of Nicorandil on Rheumatoid Arthritis PatientsNCT07730723 · Phase 2 / Phase 3 · Ain Shams University · starts Sep 6, 2026
- HRV Variation in Rheumatoid ArthritisNCT07878975 · Not reported · University of Central Florida · starts Sep 1, 2026
- Twenty-four Hour Movement Behaviors and Atherosclerotic RiskNCT07774507 · Not reported · São Paulo State University · starts Sep 1, 2026
Trials Authorized in Canada
The 10 newest of 58; search them all in Canada trials| Nov 13, 2026 | A phase 2a, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of mk-8690 in participants with rheumatoid arthritisMK-8690 | Merck & Co. (MSD) | Pending |
| Nov 7, 2025 | A multicentre, parallel-group, phase II, randomised, double-blind, 4 arm study to evaluate efficacy and safety of azd1163 in participants with moderately-to…AZD1163 | AstraZeneca Pharmaceuticals LP | Ongoing |
| Aug 22, 2025 | A phase 2b, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of tulisokibart in participants with rheumatoid arthritisTULISOKIBART (MK-7240) | Merck & Co. (MSD) | Ongoing |
| Aug 19, 2025 | A phase 2, multicenter, platform study of targeted therapies for the treatment of adult subjects with moderately to severely active rheumatoid arthritisLUTIKIZUMAB (ABT-981) / RAVAGALIMAB (ABBV-323) | AbbVie | Ongoing |
| Dec 30, 2024 | Allogeneic hematopoietic cell transplantation for refractory rheumatoid arthritis - a pilot trialANTI-THYMOCYTE GLOBULIN / FLUDABARINE / CYCLOPHOSPHAMIDE / ALLOGENEIC… | UNIVERSITY OF CALGARY | Pending |
| Sep 25, 2023 | A phase 2, randomized, double-blind, placebo-controlled, dose-ranging, efficacy and safety study of sar441566 plus methotrexate in adults with…BALINATUNFIB (SAR441566) | SANOFI-AVENTIS CANADA INC | Closed |
| Jul 21, 2023 | A phase 2, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of rosnilimab in subjects with moderate to severe rheumatoid…ROSNILIMAB | ANAPTYSBIO INC | Closed |
| Jun 9, 2023 | A phase 1b, randomized, placebo-controlled, multi-center study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of imvotamab in…IGM-2323 | IGM BIOSCIENCES, INC. | Pending |
| May 16, 2023 | A phase 3b/4 randomized, double-blind, double-dummy, active comparatorcontrolled study, comparing the efficacy and safety of upadacitinib versus adalimumab in…UPADACITINIB (ABT-494)/ ADALIMUMAB | AbbVie | Closed |
| Apr 28, 2023 | Fecal microbial transplantation for rheumatoid arthritis: a proof of concept trial (femitra trial)FECAL MICROBIOTA TRANSPLANTATION | ST JOSEPHS HEALTH CENTRE LONDON | Ongoing |
FDA Orphan Designations
Approved first, then open designations, newest first; 15 of 17| Sep 30, 2014 | HumiraReducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and… | AbbVie Inc. | Approved |
| May 9, 2013 | ILARISTreatment of active Systemic Juvenile Idiopathic Arthritis (SJIA) in patients aged 2 years and older. | Novartis Pharmaceuticals Corporation | Approved |
| Feb 21, 2008 | HumiraReducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 4 years of age and… | AbbVie Inc. | Approved |
| Aug 11, 2005 | MobicFor relief of the signs and symptoms of pauciarticular or polyarticular course Juvenile Rheumatoid Arthritis in patients 2 years of age or… | Avondale Pharmaceuticals | Approved |
| May 27, 1999 | EnbrelReducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis (JIA) in patients ages 2 and older | Immunex Corporation | Approved |
| Jan 11, 2017 | protoplasmic protein matrix, omega-3 fatty oils, vitamins,…Treatment of juvenile rheumatoid arthritis. | Leonard S. Girsh, MD | Designated |
| Apr 1, 2013 | Kre-CelazineTreatment of juvenile rheumatoid arthritis joint and related tissue inflammation in the pediatric population | All American Pharmaceutical & Natural Foods Corpor | Designated |
| May 5, 2008 | nabumetoneTreatment of pediatric juvenile rheumatoid arthritis | Cook Pharma | Designated |
| Apr 4, 2005 | Interleukin-1 TrapTreatment of Still's disease including juvenile rheumatoid arthritis and adult-onset Still's disease | Regeneron Pharmaceuticals, Inc. | Designated |
| Mar 16, 2004 | rofecoxibTreatment of juvenile rheumatoid arthritis | MERCK & Co., Inc. | Designated |
| May 25, 2001 | human gammaglobulinTreatment for juvenile rheumatoid arthritis | Latona Life Sciences, Inc. | Designated |
| Oct 14, 1998 | interferon Beta-1aTreatment of juvenile rheumatoid arthritis. | Biogen, Inc. | Designated |
| Feb 9, 1995 | Purified type II collagenTreatment of juvenile rheumatoid arthritis. | AutoImmune, Inc. | Designated |
| Jul 27, 1994 | Gammalinolenic acidTreatment of juvenile rheumatoid arthritis. | Zurier, Robert B. M.D. | Designated |
| Aug 23, 1993 | methotrexateTreatment of juvenile rheumatoid arthritis. | Wyeth-Ayerst Laboratories | Designated |
Medicines Authorised in the EU
Newest first; 15 of 41| Apr 27, 2026 | Tuyorytocilizumab · biosimilar | Chemical Works of Gedeon Richter Plc. (Gedeon Richter Plc.) | EMA ↗ |
| Apr 23, 2026 | Fubelvetanercept · biosimilar | Biosimilar Collaborations Ireland Limited | EMA ↗ |
| Feb 10, 2026 | Gotenfiagolimumab · biosimilar | Stada Arzneimittel AG | EMA ↗ |
| Nov 17, 2025 | Gobivazgolimumab · biosimilar | Advanz Pharma Limited | EMA ↗ |
| Feb 14, 2025 | Avtozmatocilizumab · biosimilar | Celltrion Healthcare Hungary Kft. | EMA ↗ |
| Sep 19, 2024 | Ituxredirituximab · biosimilar | Reddy Holding GmbH | EMA ↗ |
| Jun 20, 2024 | Tosmova (previously Tocilizumab STADA and Tofidence)tocilizumab · biosimilar | STADA Arzneimittel AG | EMA ↗ |
| Sep 15, 2023 | Tyennetocilizumab · biosimilar | Fresenius Kabi Deutschland GmbH | EMA ↗ |
| Nov 15, 2021 | Hukyndraadalimumab · biosimilar | Stada Arzneimittel AG | EMA ↗ |
| Nov 12, 2021 | Libmyrisadalimumab · biosimilar | Stada Arzneimittel AG | EMA ↗ |
| Feb 11, 2021 | Yuflymaadalimumab · biosimilar | Celltrion Healthcare Hungary Kft. | EMA ↗ |
| Sep 24, 2020 | Jyselecafilgotinib | Alfasigma S.p.A. | EMA ↗ |
| May 20, 2020 | Nepextoetanercept · biosimilar | Biosimilar Collaborations Ireland Limited | EMA ↗ |
| Feb 13, 2020 | Amsparityadalimumab · biosimilar | Pfizer Europe MA EEIG | EMA ↗ |
| Dec 16, 2019 | Rinvoqupadacitinib | AbbVie Deutschland GmbH & Co. KG | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA